Compare MAR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAR | BSX |
|---|---|---|
| Founded | 1927 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2B | 93.4B |
| IPO Year | 2005 | 2010 |
| Metric | MAR | BSX |
|---|---|---|
| Price | $357.72 | $63.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $346.63 | $102.19 |
| AVG Volume (30 Days) | 1.3M | ★ 14.3M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | 14.17 | ★ 55.20 |
| EPS | ★ 9.51 | 1.94 |
| Revenue | ★ $26,186,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | $304.41 | $11.91 |
| Revenue Next Year | $5.36 | $10.26 |
| P/E Ratio | $37.81 | ★ $32.46 |
| Revenue Growth | 4.33 | ★ 12.49 |
| 52 Week Low | $212.53 | $60.59 |
| 52 Week High | $370.00 | $109.50 |
| Indicator | MAR | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 35.16 |
| Support Level | $312.30 | N/A |
| Resistance Level | $370.00 | $76.77 |
| Average True Range (ATR) | 8.02 | 1.77 |
| MACD | 3.91 | 0.04 |
| Stochastic Oscillator | 99.64 | 22.48 |
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.